JCR Pharmaceuticals Co. Ltd. has received approval from Germany’s Paul-Ehrlich Institute (PEI) for its clinical trial application (CTA) for JR-441, a blood-brain barrier penetrating form of heparan N-sulfatase developed using JCR’s proprietary J-Brain Cargo technology.